Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FIGS vs SKIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FIGS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–0 Matrix Metrics)

FIGS Overall Winner 6-Pillar Tally: FIGS 5 – 1 SKIN Matrix Metrics: FIGS 9 – 0 SKIN

As of Nov 16, 2026, FIGS, Inc. (FIGS) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FIGS carries a Unified Composite Score of 43.7/100 (HOLD) at $21.34 (49.2x Forward P/E, 9.7% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FIGS vs SKIN
FIGS NYSE Head-to-Head Winner
FIGS, Inc.
Apparel & Other Finishd Prods Of Fabrics & Similar Matl
$21.34
-3.22% 1D
Market Cap $3.7B
TTM Revenue $749M
Forward P/E 49.2x
Beta / 30D Vol 1.10β · 59% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 30.0 Fund 35.0 Flow 68.0 Mom 1.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (17.4% over 20 days), RSI 57
RSI-14: 56.9 · SMA20: $21.14 · SMA50: $17.21
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (314.8% over 20 days), RSI 67
RSI-14: 67.4 · SMA20: $12.50 · SMA50: $6.24

6-Pillar Scorecard Institutional Category Breakdown (FIGS 5 – 1 SKIN)

Columns: Metric · FIGS · SKIN
1. Valuation Multiples FIGS
Forward P/E 49.2x 106.4x
Trailing P/E 58.0x 106.4x
PEG Ratio N/M 0.93x
EV / Revenue 4.9x 0.9x
2. Growth & Scale FIGS
Revenue Growth (YoY) +25.7% -2.1%
Earnings Growth (YoY) +100.0% +0.0%
TTM Revenue (USD) $749M $289M
Market Cap $3.7B $106.3M
3. Profitability & Quality FIGS
Gross Margin 67.7% 67.2%
Operating Margin 9.7% 2.4%
Net Profit Margin 9.7% -6.3%
Return on Equity (ROE) 16.8% -30.1%
4. Balance Sheet & Cash Flow FIGS
Cash Generation (TTM) $148M $17M
Cash Flow Margin 19.7% 5.8%
Net Cash / Leverage $9.5M Net Cash $161M Net Debt (6.61x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FIGS
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 77.0% (38th %ile) 517.4% (100th %ile)
Put/Call OI Skew 0.14x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 58.0% of Rev ($434M) 64.8% of Rev ($187M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Apparel Manufacturing Operator Household & Personal Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FIGS (9) vs SKIN (0)
Institutional Metric FIGS SKIN Criterion Row Edge
Market Capitalization
Scale
$3.7B $106.3M Larger Scale FIGS
Trailing P/E Ratio
Valuation
58.0x 106.4x Lower Multiple FIGS
Forward P/E Ratio
Valuation
49.2x 106.4x Lower Multiple FIGS
Revenue Growth (YoY)
Growth
+25.7% -2.1% Higher Growth FIGS
Operating Margin (TTM)
Profitability
9.7% 2.4% Higher Margin FIGS
Net Profit Margin
Profitability
9.7% -6.3% Higher Margin FIGS
Return on Equity (ROE)
Capital Efficiency
16.8% -30.1% Higher ROE FIGS
52-Week Range Position
Momentum
84% ($9–$24) 83% ($0–$18) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.10β · 59% Vol -14.22β · 192% Vol Lower Realized Risk FIGS
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite FIGS
Trailing 12M Revenue (USD)
Operating Scale
$749M $289M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.7% 67.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev 0.93x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$148M ($9.5M Net Cash) $17M ($161M Net Debt (6.61x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +30.91 pp
FIGS: +11.61% · SKIN: +42.52%
3M Horizon SKIN +2357.62 pp
FIGS: +50.71% · SKIN: +2408.33%
6M Horizon SKIN +2299.57 pp
FIGS: +85.57% · SKIN: +2385.14%
1Y Horizon SKIN +930.67 pp
FIGS: +127.02% · SKIN: +1057.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FIGS Revenue SKIN Revenue FIGS Op. Margin SKIN Op. Margin Margin Leader
FY2019 $110M $170M -0.3% 8.1% SKIN
FY2020 $260M $120M 22.0% -14.4% FIGS
FY2021 $420M $260M 2.6% -15.4% FIGS
FY2022 $510M $370M 7.4% -7.1% FIGS
FY2023 $550M $400M 6.2% -32.9% FIGS
FY2024 $560M $330M 0.4% -20.3% FIGS
FY2025 $630M $300M 6.0% -6.9% FIGS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FIGS BREAKOUT
22d in phase · OBV NEUTRAL
Current IV 77.0%
IV Percentile 38th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact FIGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FIGS Moat Profile Cyclical / Execution-Driven Positioning
Apparel Manufacturing Operator
Competes within the Apparel Manufacturing value chain with $3.7B market capitalization and 9.7% operating margin.
OpEx & R&D Reinvestment 58.0% of Rev ($434M)
90D Engineering Disclosures 0 Published
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published

Investor FAQ FIGS vs SKIN Key Questions & Quantitative Answers

As of Nov 16, 2026, FIGS, Inc. (FIGS) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FIGS carries a Unified Composite Score of 43.7/100 (HOLD) at $21.34 (49.2x Forward P/E, 9.7% operating margin), whereas SKIN carries 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin). Technically, FIGS sits in a Markup phase (RSI 56.9, BREAKOUT options structure) and SKIN sits in a Markup phase (RSI 67.4, UNCLASSIFIED options structure).

FIGS leads the Growth & Scale pillar: FIGS posts +25.7% YoY revenue growth and +100.0% YoY earnings growth on $749M TTM revenue (67.7% gross margin, 9.7% operating margin), compared with SKIN at -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FIGS cumulative revenue shifted +472.7% while SKIN shifted +76.5%. In operating R&D and SG&A reinvestment, FIGS deploys 58.0% of Rev ($434M) (0 90-day corporate R&D disclosures) versus 64.8% of Rev ($187M) (0 disclosures) for SKIN.

FIGS screens cheaper on headline valuation multiples. FIGS trades at 49.2x Forward P/E, 58.0x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (19.7% FCF margin), whereas SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FIGS (16.8% ROE) versus SKIN (-30.1% ROE) capital efficiency.

In options market volatility and institutional positioning, FIGS carries 77.0% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.10β · 59% Vol realized risk). By comparison, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.